Invention Grant
US5614372A Early detection of prostate cancer (CAP) by employing prostate specific
antigen (PSA) and human glandular kallikrein (hGK-1)
失效
通过使用前列腺特异性抗原（PSA）和人腺激肽释放酶（hGK-1）来早期检测前列腺癌（CAP）
- Patent Title: Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
- Patent Title (中): 通过使用前列腺特异性抗原（PSA）和人腺激肽释放酶（hGK-1）来早期检测前列腺癌（CAP）
-
Application No.: US394033Application Date: 1995-02-24
-
Publication No.: US5614372APublication Date: 1997-03-25
- Inventor: Hans Lilja , .ANG.ke Lundwall , Janita Lovgren
- Applicant: Hans Lilja , .ANG.ke Lundwall , Janita Lovgren
- Assignee: Lilja; Hans,Lundwall; Angstrom Ke,Loevgren; Janita
- Current Assignee: Lilja; Hans,Lundwall; Angstrom Ke,Loevgren; Janita
- Main IPC: G01N33/53
- IPC: G01N33/53 ; C07K16/40 ; G01N33/573 ; G01N33/574
Abstract:
The invention relates to a bioaffinity assay of prostate-specific antigen (PSA) comprising the measurement of either the concentration of total PSA (PSA-T), the concentration of free form of PSA (PSA-F) or the concentration of PSA complexed to alpha-1-antichymotrypsin (PSA-ACT), PSA-T being the sum of PSA-F and PSA-ACT. According to the invention, additionally the concentration of human glandular kallikrein (hGK-1) is measured. The concentrations of PSA-T and hGK-1 can be measured in one single assay or in separate assays. The sum of the concentrations of PSA-T and hGK-1 is used to determine the ratio a) PSA-F/(PSA-T+hGK-1) and/or b) PSA-ACT/(PSA-T+hGK-1). Both of these ratios are shown to have clinical utility for the discrimination of prostate cancer and benign prostatic hyperplasia.
Public/Granted literature
Information query
IPC分类:
